LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Suletud

SektorTervishoid

1.5 2.04

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.46

Max

1.56

Põhinäitajad
By Trading Economics
Sissetulek	-16M -13M
Müük	-15M 14M
Kasumimarginaal	-90.037
Töötajad	103
EBITDA	-16M -10M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+174.15% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. märts 2026

Turustatistika
By TradingEconomics
Turukapital	53M 547M
Eelmine avamishind	-0.54
Eelmine sulgemishind	1.5

Uudiste sentiment

By Acuity

50%

149 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. veebr 2026, 22:53 UTC

Omandamised, ülevõtmised, äriostud

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23. veebr 2026, 22:36 UTC

Tulu

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23. veebr 2026, 22:32 UTC

Tulu

Woodside Energy Fiscal Year Net Profit Falls 24%

23. veebr 2026, 23:58 UTC

Market Talk

Tulu

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23. veebr 2026, 23:58 UTC

Market Talk

Tulu

Global Energy Roundup: Market Talk

23. veebr 2026, 23:47 UTC

Market Talk

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23. veebr 2026, 23:43 UTC

Market Talk

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23. veebr 2026, 23:41 UTC

Omandamised, ülevõtmised, äriostud

Crescent Capital Partners Owns 53% of ClearView Wealth

23. veebr 2026, 23:40 UTC

Omandamised, ülevõtmised, äriostud

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23. veebr 2026, 23:40 UTC

Omandamised, ülevõtmised, äriostud

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23. veebr 2026, 23:40 UTC

Market Talk

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23. veebr 2026, 23:40 UTC

Omandamised, ülevõtmised, äriostud

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23. veebr 2026, 23:39 UTC

Omandamised, ülevõtmised, äriostud

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23. veebr 2026, 23:31 UTC

Tulu

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23. veebr 2026, 23:31 UTC

Tulu

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23. veebr 2026, 23:28 UTC

Tulu

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23. veebr 2026, 23:28 UTC

Tulu

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23. veebr 2026, 23:28 UTC

Tulu

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23. veebr 2026, 23:27 UTC

Tulu

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23. veebr 2026, 23:24 UTC

Market Talk

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23. veebr 2026, 22:38 UTC

Omandamised, ülevõtmised, äriostud

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23. veebr 2026, 22:31 UTC

Tulu

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23. veebr 2026, 22:24 UTC

Tulu

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23. veebr 2026, 22:22 UTC

Tulu

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23. veebr 2026, 22:22 UTC

Tulu

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23. veebr 2026, 22:22 UTC

Tulu

Viva Energy FY Underlying Ebitda A$700.9 Million

23. veebr 2026, 22:22 UTC

Tulu

Viva Energy Final Dividend 3.94 Australian Cents/Security

23. veebr 2026, 22:21 UTC

Tulu

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23. veebr 2026, 22:21 UTC

Tulu

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23. veebr 2026, 22:20 UTC

Tulu

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

174.15% tõus

12 kuu keskmine prognoos

Keskmine 4.03 USD 174.15%

Kõrge 6 USD

Madal 2.1 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

149 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.